Microdosing psychedelics, according to James Fadiman Grandfather of Microdosing Psychedelics, is at a level that is sub-perceptual. In other words, not psycho-active in any way. What’s exciting about microdosing psychedelics is that it is sustainable. Building new neural pathways is subtle and fully participatory. However, MDMA has not been included in the list of microdosing psychedelics.
The current practice of microdosing includes substances such as psilocybin, LSD, and cannabis, which proponents claim offer various therapeutic benefits without leading to intense psychoactive experiences. Since the definition of microdose is a sub-perceptual amount, MDMA has traditionally not been included in this category. However, in my private practice, I have been increasingly curious about the potential effects and benefits of low doses of MDMA. This study explores psychedelics at low thresholds for pain relief.
A 64-year-old male patient who experienced traumatic life events and neuropathic pain following oncological chemotherapy was treated with medium to high doses of lysergic acid diethylamide (LSD) and both high doses and microdoses of methylenedioxymethamphetamine (MDMA). Initially, the patient did not notice any acute subjective effects from LSD at a dose of 200 µg. However, after increasing the dose to 400 µg, he started to experience uplifting acute effects, and the first enduring therapeutic benefits emerged. Transitioning from LSD to MDMA, given at high doses (150-175 mg) and repeated low doses (12.5-25 mg), the patient demonstrated remarkable improvements in neuropathic pain that continued even after stopping the MDMA treatment. While the research on MDMA mini/microdosing is still in its early stages, this case beautifully illustrates the promising potential of low doses of MDMA in addressing pain disorders, paving the way for further exploration of MDMA’s positive effects on pain relief.
Psychedelic Integration Read More
